<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Transcriptome-Conditioned Personalized De Novo Drug Generation for AML Using Metaheuristic Assembly and Target-Driven Filtering - Health AI Hub</title>
    <meta name="description" content="This paper introduces a novel, end-to-end computational framework that integrates patient-specific transcriptomics with de novo drug discovery to generate perso">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Transcriptome-Conditioned Personalized De Novo Drug Generation for AML Using Metaheuristic Assembly and Target-Driven Filtering</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.21301v1" target="_blank">2512.21301v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-24
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Abdullah G. Elafifi, Basma Mamdouh, Mariam Hanafy, Muhammed Alaa Eldin, Yosef Khaled, Nesma Mohamed El-Gelany, Tarek H. M. Abou-El-Enien
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, q-bio.QM
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.98 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.21301v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.21301v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces a novel, end-to-end computational framework that integrates patient-specific transcriptomics with de novo drug discovery to generate personalized lead compounds for Acute Myeloid Leukemia (AML). By analyzing TCGA-LAML RNA-seq data, prioritizing biomarkers, and employing a metaheuristic assembly algorithm, the study identified pharmacologically viable and drug-like ligand candidates, demonstrating a blueprint for precision oncology.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is crucial for addressing the unmet need for personalized therapies in AML, a highly heterogeneous cancer. By providing a computational pipeline to discover patient-specific drug leads, it aims to improve treatment efficacy and reduce relapse rates in precision oncology.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>This research applies AI and advanced computational methods to health and medicine through: 1) AI-driven biomarker prioritization from patient transcriptomics. 2) Utilizing AI (AlphaFold3) for predictive modeling of protein structures of drug targets. 3) Developing novel metaheuristic algorithms and multi-objective optimization for generative de novo drug design, assembling novel ligands tailored to specific targets. 4) Computational validation of drug candidates via ADMET profiling and molecular docking. The overall application is AI-powered, personalized drug discovery for precision oncology.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses AML's clinical challenge of molecular heterogeneity and high relapse rates by proposing a personalized drug discovery approach.</li>
                    
                    <li>Utilized Weighted Gene Co-expression Network Analysis (WGCNA) on TCGA-LAML bulk RNA-seq data to prioritize 20 high-value biomarkers, including metabolic transporters (e.g., HK3) and immune-modulatory receptors (e.g., SIGLEC9).</li>
                    
                    <li>Modeled the physical structures of prioritized targets using AlphaFold3 and mapped druggable hotspots via the DOGSiteScorer engine.</li>
                    
                    <li>Developed a novel reaction-first evolutionary metaheuristic algorithm with multi-objective optimization to assemble unique ligands from fragment libraries, guided by spatial alignment to target hotspots.</li>
                    
                    <li>The generative model produced structurally unique chemical entities exhibiting strong drug-like properties, with QED scores peaking between 0.5 and 0.7.</li>
                    
                    <li>Validated candidates through ADMET profiling and SwissDock molecular docking, identifying high-confidence leads such as Ligand L1, which achieved a binding free energy of -6.571 kcal/mol against the A08A96 biomarker.</li>
                    
                    <li>Demonstrates the feasibility of integrating systems biology with metaheuristic molecular assembly to produce patient-tailored, pharmacologically viable drug leads for precision oncology.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study employed an end-to-end computational framework starting with bulk RNA sequencing data (TCGA-LAML cohort) analyzed by Weighted Gene Co-expression Network Analysis (WGCNA) to prioritize biomarkers. Target protein structures were modeled using AlphaFold3, and druggable hotspots were identified by DOGSiteScorer. A novel reaction-first evolutionary metaheuristic algorithm, coupled with multi-objective optimization, was developed to assemble novel ligands from fragment libraries, spatially guided by the identified hotspots. Candidate ligands were then validated through ADMET profiling and SwissDock molecular docking.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The framework successfully prioritized 20 high-value AML biomarkers, including HK3 and SIGLEC9. The generative model produced structurally unique compounds with favorable drug-like properties (QED scores 0.5-0.7). High-confidence lead candidates, such as Ligand L1, were identified, demonstrating strong binding affinity (e.g., -6.571 kcal/mol against A08A96). These results confirm that integrating systems biology and metaheuristic assembly can yield pharmacologically viable, patient-tailored drug leads.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This research provides a scalable computational blueprint for personalized drug discovery, potentially enabling the rapid identification of patient-specific therapeutic candidates for AML. This could lead to more effective, tailored treatments, mitigate molecular heterogeneity-driven treatment resistance, and ultimately improve patient outcomes in precision oncology settings.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>Not explicitly mentioned in the abstract, but as an *in silico* study, implicit limitations would include the need for experimental validation (e.g., *in vitro* and *in vivo*) to confirm drug efficacy, safety, and pharmacokinetic profiles.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The study offers a 'scalable blueprint for precision oncology in AML and beyond,' suggesting future work involves expanding this framework to a broader range of AML patients and other cancer types, as well as advancing these computationally generated leads into experimental validation phases.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Hematology</span>
                    
                    <span class="tag">Personalized Medicine</span>
                    
                    <span class="tag">Drug Discovery and Development</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">AML</span>
                    
                    <span class="tag tag-keyword">Transcriptomics</span>
                    
                    <span class="tag tag-keyword">De Novo Drug Design</span>
                    
                    <span class="tag tag-keyword">Metaheuristic Optimization</span>
                    
                    <span class="tag tag-keyword">WGCNA</span>
                    
                    <span class="tag tag-keyword">AlphaFold3</span>
                    
                    <span class="tag tag-keyword">Drug-likeness</span>
                    
                    <span class="tag tag-keyword">Molecular Docking</span>
                    
                    <span class="tag tag-keyword">Precision Oncology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Acute Myeloid Leukemia (AML) remains a clinical challenge due to its extreme molecular heterogeneity and high relapse rates. While precision medicine has introduced mutation-specific therapies, many patients still lack effective, personalized options. This paper presents a novel, end-to-end computational framework that bridges the gap between patient-specific transcriptomics and de novo drug discovery. By analyzing bulk RNA sequencing data from the TCGA-LAML cohort, the study utilized Weighted Gene Co-expression Network Analysis (WGCNA) to prioritize 20 high-value biomarkers, including metabolic transporters like HK3 and immune-modulatory receptors such as SIGLEC9. The physical structures of these targets were modeled using AlphaFold3, and druggable hotspots were quantitatively mapped via the DOGSiteScorer engine. Then developed a novel, reaction-first evolutionary metaheuristic algorithm as well as multi-objective optimization programming that assembles novel ligands from fragment libraries, guided by spatial alignment to these identified hotspots. The generative model produced structurally unique chemical entities with a strong bias toward drug-like space, as evidenced by QED scores peaking between 0.5 and 0.7. Validation through ADMET profiling and SwissDock molecular docking identified high-confidence candidates, such as Ligand L1, which achieved a binding free energy of -6.571 kcal/mol against the A08A96 biomarker. These results demonstrate that integrating systems biology with metaheuristic molecular assembly can produce pharmacologically viable, patient tailored leads, offering a scalable blueprint for precision oncology in AML and beyond</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>